Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pyxis Oncology, Inc.PYXS · Entity 5986 | Director · CEO & Chairman of the Board | September 04, 2026 | September 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pyxis Oncology, Inc.
Report date September 04, 2026 · Filed September 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.89 · Expires 2036-09-04 | Direct | 2,503,050 |
Reported balance
After 2026-09-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-04 · Grant · Acquired 2,503,050 · Balance 2,503,050 F1: The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of September 4, 2026 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of September 4, 2026 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
FIVE PRIME THERAPEUTICS, INC.
Report date April 16, 2021 · Filed April 19, 2021
Section 16 reporting ended · disclosed 2021-04-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 1
1 source rowRow 1 · 2021-04-16 · Disposition to issuer · Disposed 68,971 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, each issued and outstanding share of common stock of the Company, par value $0.001 per share ("Common Stock"), was converted into the right to receive $38.00 per share (the "Offer Price") in cash, without interest, minus any applicable withholding taxes. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.72 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-04-16 · Disposition to issuer · Disposed 480,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option. F3: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, each issued and outstanding share of common stock of the Company, par value $0.001 per share ("Common Stock"), was converted into the right to receive $38.00 per share (the "Offer Price") in cash, without interest, minus any applicable withholding taxes.
F2: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option.
F3: Not applicable.
Foundation Medicine, Inc.
Report date July 31, 2018 · Filed August 02, 2018
Section 16 reporting ended · disclosed 2018-08-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-07-31 transaction · row 1
1 source rowRow 1 · 2018-07-31 · Other · Disposed 33,421 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F2: The amount reported represents the number of unvested restricted stock units cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share multiplied by (2) the number of shares represented by such unvested restricted stock units, without interest and less any required withholding taxes. Payments are subject to the original vesting schedule and vesting conditions applicable to the underlying unvested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company.
F2: The amount reported represents the number of unvested restricted stock units cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share multiplied by (2) the number of shares represented by such unvested restricted stock units, without interest and less any required withholding taxes. Payments are subject to the original vesting schedule and vesting conditions applicable to the underlying unvested restricted stock units.
Repare Therapeutics Inc.
Report date January 28, 2026 · Filed January 29, 2026
Section 16 reporting ended · disclosed 2026-01-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-01-28 transaction · row 1
1 source rowRow 1 · 2026-01-28 · Disposition to issuer · Disposed 7,500 · Balance 0 F1: Pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the "Arrangement Agreement"), by and between the Issuer and XenoTherapeutics, Inc. (the "Parent"), Xeno Acquisition Corp. (the "Purchaser"), and XOMA Royalty Corporation ("XRC"), in exchange for (i) $2.20 in cash per share, plus (ii) one non-transferable contingent value right ("CVR") per share. F2: Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the "Arrangement Agreement"), by and between the Issuer and XenoTherapeutics, Inc. (the "Parent"), Xeno Acquisition Corp. (the "Purchaser"), and XOMA Royalty Corporation ("XRC"), in exchange for (i) $2.20 in cash per share, plus (ii) one non-transferable contingent value right ("CVR") per share.
F2: Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2026 Filed Sep 8, 2026 11:41 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to Buy) · Derivative | 2,503,050 | $0.00 Strike: $3.89 | $0.00 |
DisclosureSEC source: 0001193125-26-384391 · ownership.xml · derivative · entry 1 Civik Thomas · CIK 0001723092 · Director · CEO & Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,503,050 Underlying: Common Stock · 2,503,050 shares Expires 2036-09-04 F1 · derivative.exercise_date: The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of September 4, 2026 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:06 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to Buy) · Derivative | 250,956 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001193125-26-352206 · ownership.xml · derivative · entry 1 Civik Thomas · CIK 0001723092 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 941,087 Underlying: Common Stock · 250,956 shares Expires 2036-02-03 F1 · derivative.exercise_date: Represents the performance-based portion of an option that was granted on February 3, 2026, which shares subject to this portion of the option were to become vested in full upon the completion of a successful financing transaction or a successful strategic transaction during the reporting person's continued service as Interim Chief Executive Officer or within six months thereafter. The performance conditions were deemed to have been met on August 12, 2026, as determined by the Board. Read SEC document |
| February 03, 2026 Filed Feb 6, 2026 01:37 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to Buy) · Derivative | 690,131 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001193125-26-039951 · ownership.xml · derivative · entry 1 Civik Thomas · CIK 0001723092 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 690,131 Underlying: Common Stock · 690,131 shares Expires 2036-02-03 F1 · derivative.exercise_date: The shares subject to this option will vest in 12 equal monthly installments, commencing on the grant date and subject to the reporting person's continued service as Interim Chief Executive Officer through the applicable vesting date. Read SEC document |
| January 28, 2026 Filed Jan 29, 2026 01:30 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | Disposition to issuerCommon Shares | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001723092-26-000002 · form4-01282026_080105.xml · nonDerivative · entry 1 Civik Thomas · CIK 0001723092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the "Arrangement Agreement"), by and between the Issuer and XenoTherapeutics, Inc. (the "Parent"), Xeno Acquisition Corp. (the "Purchaser"), and XOMA Royalty Corporation ("XRC"), in exchange for (i) $2.20 in cash per share, plus (ii) one non-transferable contingent value right ("CVR") per share. F2 · price: Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 12:57 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to Buy) · Derivative | 36,979 | $0.98 Strike: $0.98 | $36,239.42 |
DisclosureSEC source: 0000950170-25-048894 · ownership.xml · derivative · entry 1 Civik Thomas · CIK 0001723092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,979 Underlying: Common Stock · 36,979 shares Expires 2035-03-31 F1 · derivative.exercise_date: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 20:35 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | GrantStock Option (right to buy) · Derivative | 27,200 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001415889-24-017654 · form4-06202024_040603.xml · derivative · entry 1 Civik Thomas · CIK 0001723092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,200 Underlying: Common Shares · 27,200 shares Expires 2034-06-16 F1 · derivative.exercise_date: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| March 26, 2024 Filed Mar 28, 2024 20:32 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to Buy) · Derivative | 44,024 | $3.83 Strike: $3.83 | $168,611.92 |
DisclosureSEC source: 0000950170-24-038098 · ownership.xml · derivative · entry 1 Civik Thomas · CIK 0001723092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,024 Underlying: Common Stock · 44,024 shares Expires 2034-03-26 F1 · derivative.exercise_date: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:22 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | GrantStock Option (right to buy) · Derivative | 27,200 | $0.00 Strike: $11.66 | $0.00 |
DisclosureSEC source: 0001209191-23-036298 · doc4.xml · derivative · entry 1 Civik Thomas · CIK 0001723092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,200 Underlying: Common Shares · 27,200 shares Expires 2033-06-07 F1 · derivative.exercise_date: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| March 24, 2023 Filed Mar 28, 2023 20:41 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantCommon Stock | 139,355 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-021404 · doc4.xml · nonDerivative · entry 1 Civik Thomas · CIK 0001723092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,186 F1 · shares: Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| May 13, 2022 Filed May 16, 2022 23:30 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | GrantStock Option (right to buy) · Derivative | 49,000 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0001209191-22-029370 · doc4.xml · derivative · entry 1 Civik Thomas · CIK 0001723092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,000 Underlying: Common Shares · 49,000 shares Expires 2032-05-13 F1 · derivative.exercise_date: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:15 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantCommon Stock | 66,831 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-012919 · form4.xml · nonDerivative · entry 1 Civik Thomas · CIK 0001723092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,831 F1 · shares: Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 18:21 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | PurchaseCommon Stock | 15,700 | $12.74 | $200,018.00 |
DisclosureSEC source: 0000899243-21-045363 · doc4.xml · nonDerivative · entry 1 Civik Thomas · CIK 0001723092 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Civik Family Trust Disclosed balance after: 15,700 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.47 to $13.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · ownership.nature: These shares are held directly by the Civik Family Trust, a revocable trust for which the Reporting Person and his spouse are the grantors. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 22:00 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | PurchaseCommon Shares | 7,500 | $28.08 | $210,600.00 |
DisclosureSEC source: 0001209191-21-065517 · doc4.xml · nonDerivative · entry 1 Civik Thomas · CIK 0001723092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $27.50 to $28.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 07, 2021 Filed Oct 12, 2021 23:47 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to buy) · Derivative | 42,191 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001140361-21-034427 · form4.xml · derivative · entry 1 Civik Thomas · CIK 0001723092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,191 Underlying: Common Stock · 42,191 shares Expires 2031-10-07 F1 · derivative.exercise_date: These stock options vest as to 1/3 of the shares covered by the option on each annual general meeting of the Issuer's stockholders following the October 7, 2021 grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:06 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | GrantStock Option (right to buy) · Derivative | 42,000 | $0.00 Strike: $33.89 | $0.00 |
DisclosureSEC source: 0001209191-21-055321 · doc4.xml · derivative · entry 1 Civik Thomas · CIK 0001723092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Shares · 42,000 shares Expires 2031-09-07 F1 · derivative.exercise_date: One-third (1/3rd) of the shares subject to the option shall vest on September 7, 2022, and one twenty-fourth (1/24th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 19:21 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 480,000 | Not disclosed Strike: $2.72 | Not disclosed |
DisclosureSEC source: 0001209191-21-027390 · doc4.xml · derivative · entry 2 Civik Thomas · CIK 0001723092 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 480,000 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 19:21 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Disposition to issuerCommon Stock | 68,971 | $38.00 | $2,620,898.00 |
DisclosureSEC source: 0001209191-21-027390 · doc4.xml · nonDerivative · entry 1 Civik Thomas · CIK 0001723092 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, each issued and outstanding share of common stock of the Company, par value $0.001 per share ("Common Stock"), was converted into the right to receive $38.00 per share (the "Offer Price") in cash, without interest, minus any applicable withholding taxes. Read SEC document |
| April 09, 2021 Filed Apr 13, 2021 13:05 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Tax withholdingCommon Stock | 11,088 | $37.94 | $420,678.72 |
DisclosureSEC source: 0001209191-21-026419 · doc4.xml · nonDerivative · entry 1 Civik Thomas · CIK 0001723092 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,971 F1 · balance_after: Includes 3,859 shares acquired on November 15, 2020 and 1,200 shares acquired on April 1, 2021, in each case, pursuant to Five Prime Therapeutics, Inc.'s 2013 Employee Stock Purchase Plan. Read SEC document |
| April 13, 2020 Filed Apr 14, 2020 16:38 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | GrantEmployee Stock Option (right to buy) · Derivative | 480,000 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001209191-20-024363 · doc4.xml · derivative · entry 2 Civik Thomas · CIK 0001723092 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,000 Underlying: Common Stock · 480,000 shares Expires 2030-04-12 F2 · derivative.exercise_date: This option will vest with respect to one-fourth (1/4) of the shares subject to this option on April 13, 2021 and with respect to one forty-eighth (1/48) of the shares subject to this option monthly thereafter, provided the reporting person provides services to the Company through each such date. Read SEC document |
| April 13, 2020 Filed Apr 14, 2020 16:38 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024363 · doc4.xml · nonDerivative · entry 1 Civik Thomas · CIK 0001723092 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 F1 · shares: Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of April 13, 2021, 2022 and 2023, provided the reporting person provides services to Five Prime Therapeutics, Inc. (the "Company") through each such date. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 16:03 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | OtherCommon Stock | 33,421 | $137.00 | $4,578,677.00 |
DisclosureSEC source: 0001209191-18-044917 · doc4.xml · nonDerivative · entry 1 Civik Thomas · CIK 0001723092 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · date: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F2 · shares: The amount reported represents the number of unvested restricted stock units cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share multiplied by (2) the number of shares represented by such unvested restricted stock units, without interest and less any required withholding taxes. Payments are subject to the original vesting schedule and vesting conditions applicable to the underlying unvested restricted stock units. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 16:07 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | GrantCommon Stock | 33,421 | $68.20 | $2,279,312.20 |
DisclosureSEC source: 0001209191-18-000779 · doc4.xml · nonDerivative · entry 1 Civik Thomas · CIK 0001723092 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,421 F1 · shares: Represents restricted stock units issued pursuant to a Restricted Stock Unit Award Agreement and the Issuer's 2013 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest (i) with respect to 25% of the units, on January 1, 2019, and (ii) with respect to 75% of the units, in 12 equal installments every three months with the first installment vesting on April 1, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.